8-18　ⓔ文献

1. Simonneau G, Montani D, et al: Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J, 2019; 53: 1801913.

2. Fukumoto Y, Shimokawa H: Recent progress in the management of pulmonary hypertension. Circ J, 2011; 75: 1801–1810.

3. 福本義弘：肺高血圧症新規治療薬のポテンシャル．血管, 2019; 42: 1–8.

4. 肺高血圧症治療ガイドライン (2017年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2017_fukuda_h.pdf

5. 循環器領域における性差医療に関するガイドライン（JCS 2010）．http://www.j-circ.or.jp/guideline/pdf/JCS2010tei.h.pdf

6. Leuchte HH, Baumgartner RA, et al: Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med, 2006; 173: 744–750.

7. Nergui S, Fukumoto Y, et al: Role of endothelial nitric oxide synthase and collagen metabolism in right ventricular remodeling due to pulmonary hypertension. Circ J, 2014; 78: 1465–1474.

8. 大林浩幸：慢性閉塞性肺疾患と併存症．日本内科学会雑誌，2018; 107: 999–1006.

9. Opitz CF, Hoeper MM, et al: Pre–capillary, combined, and post–capillary pulmonary hypertension: A pathophysiological continuum. J Am Coll Cardiol, 2016; 68: 368–378.

10. Miura Y, Fukumoto Y, et al: Identification of new prognostic factors of pulmonary hypertension. Circ J, 2010; 74: 1965–1971.

11. Tatebe S, Fukumoto Y, et al: Enhanced [18F]fluorodeoxyglucose accumulation in the right ventricular free wall predicts long–term prognosis of patients with pulmonary hypertension: a preliminary observational study. Eur Heart J Cardiovasc Imaging, 2014; 15: 666–672.

12. van de Veerdonk MC, Kind T, et al: Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol, 2011; 58: 2511–2519.

13. 三嶋理晃：COPDの予後．日本内科学会雑誌，2015; 104: 1115–1121.

14. 一ノ瀬正和：COPD（慢性閉塞性肺疾患）診断と治療のためのガイドライン2018．日本内科学会雑誌，2018; 107: 2306–2309.